[Gynecologic malignancies].
Clinical Value of tumor markers in gynecologic malignancies is discussed with regard to their possible role in the future. Generally, the first choices of tumor markers include SCC antigen for squamous cell carcinoma and CA125 for adenocarcinoma and uterine sarcoma. Also, recent data regarding the biological function of some tumor markers, e.g., inhibition of cysteine protease by SCC antigen, have provided new information for understanding the malignant behavior of tumor cells, which would be useful for setting up new diagnostic and therapeutic modalities against malignant tumor in the future.
Kato
H
H
Department of Obstetrics and Gynecology, Yamaguchi University School of Medicine.
D000951:Antigens, Neoplasm / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis*; D018394:CA-125 Antigen / Q000032:analysis; D002822:Choriocarcinoma / Q000175:diagnosis; D005260:Female; D005833:Genital Neoplasms, Female / Q000175:diagnosis*; D006801:Humans; D010051:Ovarian Neoplasms / Q000175:diagnosis; D015843:Serpins; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis; D014594:Uterine Neoplasms / Q000175:diagnosis
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D015843:Serpins; C051072:squamous cell carcinoma-related antigen